Guidance

Respiratory Syncytial Virus (RSV) vaccine: PGD template

Patient Group Direction (PGD) template to support the national vaccination programme for pregnant women to protect infants and older adults aged 75 years and above and residents in care homes for older adults.

• From: UK Health Security Agency
• Published: 29 July 2024
• Last updated: 17 February 2026 — See all updates

Applies to England

Documents

RSV vaccine Patient Group Direction (PGD)

Ref: GOV-20340

MS Word Document, 173 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This PGD template supports the administration of the RSV vaccine to:

• women from 28 weeks of pregnancy
• older adults aged 75 years and above
• residents in care homes for older adults

in accordance with the national programme as outlined in the RSV letter and the RSV Green Book chapter.

The RSV vaccine PGD version 2.0 is valid from 1 April 2026 to 28 February 2029.

Practitioners must not use this template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.

Published 29 July 2024

Last updated 17 February 2026 + show all updates

1. 17 February 2026

   Updated PGD form.

2. 29 July 2024

   First published.